Search filters

List of works by Diana Wattie

Absence of Somatic SQSTM1 Mutations in Paget’s Disease of Bone

scientific article published in February 2009

Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's disease.

scientific article published on 21 December 2001

Bone metabolism during long-term treatment with imatinib

scientific article published on 24 January 2013

Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.

scientific article

Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib

scientific article published on 27 January 2009

Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial

scientific article published on 5 July 2005

Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial

scientific article published on 24 March 2012

Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms

scientific article published on 01 November 2007

Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone

scientific article

Paget's disease of bone in New Zealand: continued decline in disease severity

scientific article published on 7 October 2004

Previous pet ownership and Paget's disease

scientific article published on 01 January 1990

Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial

scientific article published in October 2010

Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD.

scientific article published on September 1987

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

scholarly article by Andrew Grey et al published July 2009 in Obstetrical and Gynecological Survey

The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women

scientific article

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

scientific article published on 30 January 2007

Paulina is supported by:

About Paulina

Help